Pharmaceutical composition containing cyclopeptide and chemotherapeutic agent or an inhibitor of angiogenesis

 

The invention relates to medicine. The claimed pharmaceutical composition, containing in its composition cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one chemotherapeutic agent, and/or one of its physiologically acceptable salts, and/or angiogenesis inhibitor and/or one of its physiologically acceptable salts, and its use for the treatment of various diseases. The invention provides the ability to use compositions in the treatment of tumors with high efficiency. 8 C. and 4 h.p. f-crystals.

Description text in facsimile form (see graphic part).

Claims

1. Pharmaceutical composition comprising cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and one or more substances, provided that these substances are selected from the group comprising an inhibitor of angiogenesis, is different from cyclo(Arg-Gly-Asp-D-Phe-NMe-Val), its physiologically acceptable salts, chemotherapeutic agent and its physiologically acceptable salts, and with the additional condition that the chemotherapeutic agent selected from the group including docetaxel, paclitaxel, carboplatin, cisplatin, 5-f is italin.

2. The pharmaceutical composition according to p. 1, containing in its composition cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one chemotherapeutic agent and/or one of its physiologically acceptable salts, wherein the chemotherapeutic agent is selected from the group comprising docetaxel, paclitaxel, carboplatin, cisplatin, 5-fluorouracil and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin and gemcitabine.

3. The pharmaceutical composition according to p. 1, containing in its composition cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one inhibitor of angiogenesis and/or one of its physiologically acceptable salts.

4. The pharmaceutical composition under item 1 or 2, containing in its composition cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its pharmaceutically acceptable salts and gemcitabine and/or one of its physiologically acceptable salts.

5. The pharmaceutical composition under item 1 or 3, wherein the angiogenesis inhibitor is selected from the group comprising inhibitorsV3andV5means, designed to combat due to pathological factors, angiogenic diseases, thrombosis, myocardial infarction, ischemic heart disease, arteriosclerosis, tumors, osteoporosis, inflammations and infections.

7. The use of the pharmaceutical composition according to any one of paragraphs.1-3 to fight due to pathological factors, angiogenic diseases, thrombosis, myocardial infarction, ischemic heart disease, arteriosclerosis, tumors, osteoporosis, inflammations and infections.

8. The use of cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts in sequence or in physical combination with a chemotherapeutic agent selected from the group comprising docetaxel, paclitaxel, carboplatin, cisplatin, 5-fluorouracil and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin and gemcitabine, and/or one of its physiologically acceptable salts, and/or an inhibitor of angiogenesis, and/or one of its physiologically acceptable salts in the manufacture of medicines designed to fight tumors.

9. The use of cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically p is the your, selected from the group including docetaxel, paclitaxel, carboplatin, cisplatin, 5-fluorouracil and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin and gemcitabine, and/or one of its physiologically acceptable salts in the manufacture of medicines designed to fight tumors.

10. The set of individual packages containing (a) an effective amount of cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and b) an effective amount of a chemotherapeutic drug selected from the group comprising docetaxel, paclitaxel, carboplatin, cisplatin, 5-fluorouracil and calcium folinate, irinotecan, cyclophosphamide, carmustine, doxorubicin, vinorelbine, goserelin and gemcitabine.

11. Pharmaceutical composition containing in its structure cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one MMP inhibitor and/or one of its physiologically acceptable salts.

12. Pharmaceutical composition containing in its structure cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one inhibitor of tyrosine kinase and/or one of its physiologically acceptable salts.

 

Same patents:

The invention relates to new derivatives of 2-aminopyridine of General formula (I)

where And denotes the radical

in which R1, R2and R3mean hydrogen, halogen, HE, alkyl or alkoxy and the other,

or radical

in which R8means hydrogen, x is the radical -(CH2)m-Q, m is an integer from 0 to 6, Y represents alkyl, alkenylphenol or alkenylphenol chain or other, R10is hydrogen or alkyl, or their salts

The invention relates to physiology, pharmacology and medicinal chemistry, in particular, to an improved method of inhibiting platelet aggregation

The invention relates to medicine, namely to experimental pharmacology and cardiology
The invention relates to cardiology and can be used to prevent reperfusion lesions of the heart after the opening of the coronary artery in patients with acute myocardial infarction

The invention relates to organic chemistry and pharmacology, namely a mixture of isomers of the potassium salt of 2-[5(6)-nitro-1-(titanyl-3)benzimidazolyl-2-thio] acetic acid in a molar ratio of 1:3, manifesting cardiotonic activity
The invention relates to the pharmaceutical industry, namely the creation of pharmaceutical compositions with a wide range of pharmacological actions on derived orotovoy acid

The invention relates to new sulfadimethoxine benzopyranones derivative of the formula I

< / BR>
where R(5) is in one of positions 5, 6, 7 and 8, and R(1) and R(2) independently of one another denote hydrogen or alkyl with 1-6 carbon atoms, R(3) means R(10)-CnH2nR(10) means a hydrogen atom or methyl, n denotes an integer equal to 0-10, R(4) means R(13)- CrH2rand one of CH2group can be replaced by-CO-O - or-O-CO - group, R(13) denotes methyl or trifluoromethyl, r is an integer equal 0-12, R(5) means-Y-CsH2s-R(18), Y represents-O-, s indicates an integer equal to 1-8, R(18) denotes hydrogen, trifluoromethyl or phenyl, R(6) means-OR(10d) or-OCOR(10d) group, R(10d) denotes hydrogen or alkyl with 1-3 carbon atoms, denotes hydrogen or R(6) and together form a bond; and their physiologically acceptable salts

The invention relates to new compounds of the formula (I):

wherein R1is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (ISO)hyalinella, tetrahydro(ISO)hyalinella, 3,4-dihydro-1H-izokhinolinom, romaniam or camphor group, and these groups optionally can be substituted by one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxyl; R2and R3independently are H or (1-8C)alkyl; R4is (1-8C)alkyl or (3-8C)cycloalkyl; or R3and R4together with the nitrogen atom to which they are linked, are a nonaromatic (4-8)membered cycle, optionally containing another heteroatom, the cycle is optionally substituted (1-8C)alkyl or SO2is(1-8C)alkyl; Q is a spacer having a chain length from 10 to 70 atoms; and Z is a negatively charged oligosaccharide residue comprising from two to six monosaccharide units, the charge is compensated by positively charged counterions, or its pharmaceutically acceptable salts or prodrugs and pharmaceutical compositions having antimicrobial activity

The invention relates to organic chemistry and pharmacology, and relates new connection - 1-(1,1-dissociator-3)-2-morpholinobenzenediazonium hydrochloride, increasing resistance to acute hypoxia with hypercapnia

The invention relates to new indole derivative of the formula I

where two of R1a, Rlb, Rlc, Rldindependently from each other denote H, F, I, Cl, Br, (C1-C4)alkyl, phenyl, phenyl-(C1-WITH4)alkyl, (C1-C4)alkoxy, phenyl-(C1-C4)alkoxy, phenyloxy, HE, -NR5aR5b, -SOn-R6c, n is 1-2, and are the same or different, and two other mean N; where all residues R5a, R5b, R6cif present in the molecule more than once, are independent from each other and may be each the same or different; one of R2and R3means -(CH2)p-CO-R8and the other denotes H, F, Cl, Br, or -(CH2)p-CO-R8; p is 0, 1 or 2; R8means-NR9R10, -OR10; A represents the bivalent residue of(C1-C4)alkyl, which is saturated or which contains a triple bond, or -(C1-C4)alkyl-CO-NH-, where the nitrogen is associated with R4; R4means phenyl, which is substituted by one residue R15bor pyridyl, which is unsubstituted or substituted14on the nitrogen atom; all their stereozoom

The invention relates to biologically compatible carriers of oxygen for administration to patients as a Supplement or partial substitution of whole blood

The invention relates to aqueous pharmaceutical compositions of erythropoietin that are free from the products of human serum, stable amino acid, sorbitan mono-9-octadecenoate poly(oxy-1,2-ethandiyl) derived
The invention relates to the field of medicine and relates to adhesive compositions to stop bleeding on the basis of factor VIII
The invention relates to the field of pharmaceutical industry

The invention relates to new compounds of General formula I

R1-A-B-D-En-R2 (I)

in which R1 represents R12C(O), and R12 is selected from the group consisting of alkenyl, alkenylacyl or alkenylamine; And is a group A1-A2-A3, where A1 represents NH, A2 is a CHR93 in which R93 is 4-amidinophenoxy; A3 represents C(O); is a group B1-B2-B3, where B1 represents NH; B2 is a CHR97 where R97 represents ethyl, which is substituted in position 2 by hydroxycarbonyl or allyloxycarbonyl; B3 represents C(O); D represents a group D1-D2-D3, where D1 represents NH, D2 represents CR81R82 where R81 and R82 are independently selected from the group consisting of hydrogen and unsubstituted or substituted residues of alkyl, aryl, arylalkyl, heteroallyl; D3 represents C(O); Enis a (E1-E2-E3)nin which n is 0 or 1; E1 represents NR70, where R70 is H; E2 represents CR71R72, where R71 and R72 include independently selected from the group consisting of hydrogen and unsubstituted or substituted residues of alkyl, aryl, arylalkyl, heteroallyl; E3 represents C(O); R2 is a NR21R22 where R21 of iillil and geterotsiklicheskikh, moreover, the alkyl contains from 1 to 13 carbon atoms, alkenyl contains from 2 to 13 carbon atoms, aryl and heteroaryl contain from 5 to 13 ring carbon atoms, where in the rest of heteroaryl one or more carbon atoms are replaced by heteroatoms selected from the group consisting of N, O and S; heteroseksualci contains from 3 to 8 ring carbon atoms, of which from one to three carbon atoms are replaced by heteroatoms selected from the group consisting of N, O and S; in any stereoisomeric forms or their mixtures in any ratio, and their pharmaceutically acceptable salts; the method of obtaining compounds of General formula I, including linking protected amino acids; to pharmaceutical compositions which are able to exert an antithrombotic effect by activated factor VII(FVIIa) blood coagulation
The invention relates to the field of pharmaceutical industry and relates to a composition for the prevention and treatment of fibrocystic mastopathy
Up!